Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTIVION, INC.AORT · Entity 4767 | Director | May 18, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTIVION, INC.
Report date May 18, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,372 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 7,576 · Balance 61,372 F1: RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NxStage Medical, Inc.
Report date February 21, 2019 · Filed February 25, 2019
Section 16 reporting ended · disclosed 2019-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 1
1 source rowRow 1 · 2019-02-21 · Disposition to issuer · Disposed 781,646 · Balance 0 F1: Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2019-03-08 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-21 · Disposition to issuer · Disposed 39,062 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.03 · Expires 2023-03-03 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-21 · Disposition to issuer · Disposed 189,456 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.66 · Expires 2024-03-09 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-21 · Disposition to issuer · Disposed 175,256 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.66 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-21 · Disposition to issuer · Disposed 205,058 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.58 · Expires 2026-03-08 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-21 · Disposition to issuer · Disposed 268,159 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.89 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-21 · Disposition to issuer · Disposed 149,567 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-09 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-21 · Disposition to issuer · Disposed 34,928 · Balance 0 F3: These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
F3: These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 21, 2026 00:32 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-037001 · wk-form4_1779323520.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,372 F1 · shares: RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:11 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 6,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-25-000105 · wk-form4_1748376652.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,796 F1 · shares: RSA Grant vests on May 22, 2026, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 12:33 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 6,289 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000195 · wk-form4_1717417977.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,471 F1 · shares: RSA Grant vests on May 30th 2025, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:42 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 9,709 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-23-000108 · wk-form4_1686260560.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,182 F1 · balance_after: RSA Grant vests on June 6th 2024, pursuant to the terms of the Equity and Cash Incentive Plan? Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:45 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 7,878 | $19.04 | $149,997.12 |
DisclosureSEC source: 0000784199-22-000147 · certent-form4.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,473 F1 · shares: Represents shares of restricted stock that cliff vest on June 1, 2023, provided the status as a Director with Artivion continues through such date. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:23 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,423 | $29.39 | $129,991.97 |
DisclosureSEC source: 0000784199-21-000171 · certent-form4.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,595 F1 · shares: Represents shares of restricted stock that cliff vest on June 1, 2022, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:45 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 5,667 | $22.94 | $130,000.98 |
DisclosureSEC source: 0000784199-20-000161 · certent-form4.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,172 F1 · shares: Represents shares of restricted stock that cliff vest on June 1, 2021, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| May 05, 2020 Filed May 7, 2020 00:20 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 1,178 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000107 · certent-form4.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,505 F1 · shares: RSA Covid grant vests on May 4, 2021, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:23 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,163 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-19-000116 · certent-form4.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,327 F1 · shares: Represents shares of restricted stock that cliff vest on May 16, 2020, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerRestricted Stock Unit · Derivative | 34,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 8 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,928 shares Expires 2020-03-09 F3 · kind: These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 149,567 | $0.00 Strike: $27.89 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 7 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 149,567 shares Expires 2027-03-08 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 268,159 | $0.00 Strike: $15.58 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 6 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 268,159 shares Expires 2026-03-08 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 205,058 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 5 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 205,058 shares Expires 2025-03-02 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 175,256 | $0.00 Strike: $14.66 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 4 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,256 shares Expires 2024-03-09 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 189,456 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 3 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,456 shares Expires 2023-03-03 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 39,062 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · derivative · entry 2 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,062 shares Expires 2019-03-08 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerCommon Stock | 781,646 | $30.00 | $23,449,380.00 |
DisclosureSEC source: 0001246360-19-000767 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:17 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,638 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-18-000113 · certent-form4.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,164 F1 · shares: Represents shares of restricted stock that cliff vest on May 23, 2019, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,273 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001246360-18-001143 · form.xml · derivative · entry 3 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,273 shares Expires 2018-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Tax withholdingCommon Stock | 28,039 | $24.05 | $674,337.95 |
DisclosureSEC source: 0001246360-18-001143 · form.xml · nonDerivative · entry 2 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,646 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 36,273 | $18.59 | $674,315.07 |
DisclosureSEC source: 0001246360-18-001143 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionRestricted Stock Unit · Derivative | 17,464 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001072 · form.xml · derivative · entry 4 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,928 Underlying: Common Stock · 17,464 shares Expires 2020-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | GrantRestricted Stock Unit · Derivative | 52,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001072 · form.xml · derivative · entry 3 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,392 Underlying: Common Stock · 52,392 shares Expires 2020-03-09 F1 · derivative.exercise_date: Award granted pursuant to the 2017 Performance Share Plan, vesting in 3 equal annual installments beginning March 9, 2018. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Tax withholdingCommon Stock | 5,167 | $24.37 | $125,919.79 |
DisclosureSEC source: 0001246360-18-001072 · form.xml · nonDerivative · entry 2 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,412 Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 17,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001072 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2017 Filed Oct 27, 2017 16:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | GiftCommon Stock | 177,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-17-002953 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761,115 Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 16:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 3,000 | $27.28 | $81,840.00 |
DisclosureSEC source: 0001246360-17-001636 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,086 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 16:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 3,000 | $26.65 | $79,950.00 |
DisclosureSEC source: 0001246360-17-001630 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,086 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| March 22, 2017 Filed Mar 23, 2017 16:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 3,000 | $27.42 | $82,260.00 |
DisclosureSEC source: 0001246360-17-001475 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945,086 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 17:42 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 3,000 | $27.72 | $83,160.00 |
DisclosureSEC source: 0001246360-17-001434 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,086 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 17:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | GrantStock Option (Right to Buy) · Derivative | 149,567 | $0.00 Strike: $27.89 | $0.00 |
DisclosureSEC source: 0001246360-17-001311 · form.xml · derivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,567 Underlying: Common Stock · 149,567 shares Expires 2027-03-08 F1 · derivative.exercise_date: The stock option becomes exercisable in 48 equal monthly installments beginning April 9, 2017. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 18:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionRestricted Stock Unit · Derivative | 28,022 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-17-001204 · form.xml · derivative · entry 3 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,022 shares Expires 2017-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 18:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Tax withholdingCommon Stock | 13,185 | $28.31 | $373,267.35 |
DisclosureSEC source: 0001246360-17-001204 · form.xml · nonDerivative · entry 2 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,086 Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 18:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 28,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-17-001204 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 17:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $28.97 | $217,275.00 |
DisclosureSEC source: 0001246360-17-001040 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,249 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 20:21 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $29.01 | $217,575.00 |
DisclosureSEC source: 0001246360-17-000952 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,749 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,591 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · derivative · entry 7 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,273 Underlying: Common Stock · 5,591 shares Expires 2018-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,697 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · derivative · entry 6 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,062 Underlying: Common Stock · 3,697 shares Expires 2019-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 123,900 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · derivative · entry 5 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123,900 shares Expires 2017-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Tax withholdingCommon Stock | 49,555 | $28.38 | $1,406,370.90 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · nonDerivative · entry 4 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,249 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 5,591 | $18.59 | $103,936.69 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · nonDerivative · entry 3 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 3,697 | $18.48 | $68,320.56 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · nonDerivative · entry 2 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:34 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 123,900 | $9.96 | $1,234,044.00 |
DisclosureSEC source: 0001246360-17-000626 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2017 Filed Jan 18, 2017 18:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $27.63 | $207,225.00 |
DisclosureSEC source: 0001246360-17-000210 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,616 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| January 17, 2017 Filed Jan 17, 2017 16:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $27.52 | $206,400.00 |
DisclosureSEC source: 0001246360-17-000182 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,116 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| December 14, 2016 Filed Dec 14, 2016 18:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $25.68 | $192,600.00 |
DisclosureSEC source: 0001246360-16-007460 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,616 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| December 13, 2016 Filed Dec 13, 2016 18:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $25.42 | $190,650.00 |
DisclosureSEC source: 0001246360-16-007453 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,116 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 18:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $24.01 | $180,075.00 |
DisclosureSEC source: 0001246360-16-007224 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,616 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 17:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,500 | $25.51 | $191,325.00 |
DisclosureSEC source: 0001246360-16-007219 · form.xml · nonDerivative · entry 1 Burbank Jeffrey H · CIK 0001341411 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,116 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.